Astaxanthin / NO Cancer Research Results

ASTX, Astaxanthin: Click to Expand ⟱
Features:

Astaxanthin — a lipophilic xanthophyll carotenoid antioxidant (often sourced from Haematococcus pluvialis microalgae and also present in salmon/crustaceans) used as a nutraceutical with prominent redox and inflammation-modulating biology. It is formally classified as a small-molecule dietary carotenoid (natural product / nutraceutical). Common abbreviations include ASTX and AXT. In oncology-context literature it is primarily discussed as a chemopreventive/cytoprotective redox modulator with context-dependent direct antitumor effects, and with theoretical concern for antagonizing ROS-mediated chemo/radiation mechanisms in some settings.
The European Commission considers natural astaxanthin as a food dye

Primary mechanisms (ranked):

  1. NRF2 pathway activation with downstream antioxidant/phase-II enzyme program (context-dependent; often cytoprotective)
  2. Suppression of inflammatory signaling including NF-κB axis with downstream COX-2/iNOS and cytokine modulation
  3. Growth/survival signaling modulation (context-dependent), commonly reported on PI3K–AKT, ERK/MAPK, STAT3
  4. Mitochondria-linked apoptosis induction and cell-cycle perturbation in select tumor models (dose/model-dependent)
  5. Anti-migration/anti-EMT phenotype (e.g., MMPs, cadherin switch; model-dependent)
  6. Ferroptosis/redox-lethal interactions reported in limited models (model-dependent)

Bioavailability / PK relevance: Poor aqueous solubility and variable oral absorption (fat/formulation-dependent). Plasma exposure is typically low with standard oral supplements; engineered formulations (micellar/nanoemulsion) can increase Cmax and shorten Tmax. Reported terminal half-life in healthy volunteers is on the order of ~1–2 days in at least one human PK study.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar astaxanthin concentrations that can exceed typical human plasma levels after supplementation; therefore, mechanistic claims are frequently concentration- and formulation-limited for systemic antitumor translation.

Clinical evidence status: Predominantly preclinical (cell/animal) for direct anticancer claims. Human evidence is stronger for oxidative stress/inflammation biomarker modulation than for anticancer efficacy endpoints; not an approved anticancer drug. Practical oncology use is mainly adjunctive/chemopreventive framing, with caution discussed around concurrent ROS-dependent chemo/radiation.

Astaxanthin is a xanthophyll carotenoid with exceptionally strong antioxidant capacity. In cancer biology, it shows context-dependent effects—largely chemopreventive and cytoprotective, with limited evidence as a direct antineoplastic agent.
Astaxanthin significantly promotes the proliferation of Akkermansia, a microorganism with enhanced anti-tumor immune effects.
Anti-inflammatory signaling, Astaxanthin can inhibit: NF-κB, COX-2, iNOS
Astaxanthin commonly Activates NRF2: Upregulates antioxidant enzymes (GSH, SOD, CAT, GPX)
-Protective in normal tissues
-Potentially tumor-protective in established cancers

Often discouraged during active chemotherapy or radiation
It may:
-Protect tumor cells from ROS-mediated killing
-Reduce lipid peroxidation-based therapies
This concern is similar to:
-Vitamin E
-Trolox
-High-dose carotenoids

Astaxanthin is less likely to be pro-oxidant than lycopene or β-carotene.
Some reports indicate a pro-oxidant effect, but at concentrations that are not achievable for in vito.

Astaxanthin — mechanistic pathway map (cancer-context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NRF2 antioxidant response ↑ NRF2 (context-dependent) → ↓ ROS injury; may blunt ROS-lethal therapies ↑ NRF2 → ↑ GSH/SOD/CAT/GPx; cytoprotection R/G Redox buffering and stress tolerance Often positioned as protective; in established tumors this can be tumor-supportive depending on therapy and redox state.
2 NF-κB inflammatory signaling ↓ NF-κB → ↓ pro-survival inflammation (model-dependent) ↓ inflammatory cytokine signaling R/G Anti-inflammatory microenvironment shift Commonly linked to ↓ COX-2/iNOS and reduced inflammatory tone.
3 PI3K–AKT survival signaling ↓ PI3K/AKT (model-dependent) → ↑ apoptosis, ↓ proliferation ↔ / mild cytoprotective bias (context-dependent) R/G Survival pathway suppression in select tumors Directionality is model- and dose-dependent; some datasets show mixed AKT effects.
4 ERK/MAPK signaling ↓ ERK/MAPK (model-dependent) → ↓ proliferation/EMT ↔ / ↓ stress-activated signaling (context-dependent) R/G Anti-growth signaling modulation Often reported alongside PI3K/AKT changes; may converge on apoptosis/cell-cycle effects.
5 STAT3 axis ↓ STAT3 → ↓ proliferation, ↓ immune-evasion programs (model-dependent) ↔ G Reduced oncogenic transcription signaling Reported in prostate and other models; typically framed as anti-tumor signaling.
6 Mitochondria-mediated apoptosis ↑ intrinsic apoptosis (BAX↑, Bcl-2↓, caspases↑; model-dependent) ↓ stress-induced apoptosis (cytoprotection) R Cell death modulation Key “anti-tumor” readout in many studies; may require higher concentrations than typical systemic exposure.
7 Cell cycle control ↑ p21/p27 and/or arrest signatures (model-dependent) ↔ G Proliferation braking Often co-occurs with apoptosis; direction varies with cell line and dosing.
8 EMT and matrix remodeling ↓ EMT; ↓ MMPs; ↑ E-cadherin (model-dependent) ↔ G Anti-migration / anti-metastatic phenotype Reported via miRNA and cadherin/MMP changes in some colon/breast models.
9 Angiogenesis signaling ↓ VEGF/EGFR signaling (limited, model-dependent) ↔ G Reduced pro-angiogenic drive Less consistently central than NRF2/NF-κB/PI3K–AKT in the literature.
10 Ferroptosis and lipid peroxidation balance ↔ / ↑ ferroptosis (limited models) but also ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation injury R Redox-lethal interaction or protection (context-dependent) Net effect depends strongly on baseline oxidative state and whether therapy relies on lipid peroxidation.
11 Clinical Translation Constraint Low/variable oral exposure; many in-vitro effects are high-concentration. Antioxidant/NRF2 biology raises a plausible antagonism risk for ROS-dependent chemo/radiation (context-dependent). Formulation and dosing strategy strongly influence exposure. — Translational ceiling Best-supported human domain is oxidative stress/inflammation biomarkers rather than anticancer efficacy endpoints.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
NO, Nitric Oxide: Click to Expand ⟱
Source:
Type:
Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells.
The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment.
Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS).

– In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer.

• Expression Patterns in Tumors:
– Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment.

– Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation.
Scientific Papers found: Click to Expand⟱
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Migration ⓘ

TumCP↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   lipid-P↓, 1,   SOD↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,  

Functional Outcomes ⓘ

AntiDiabetic↓, 1,   cardioP↑, 1,  
Total Targets: 13

Scientific Paper Hit Count for: NO, Nitric Oxide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:382  Target#:563  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page